Cargando…
Polymeric Carriers for Delivery of RNA Cancer Therapeutics
As research uncovers the underpinnings of cancer biology, new targeted therapies have been developed. Many of these therapies are small molecules, such as kinase inhibitors, that target specific proteins; however, only 1% of the genome encodes for proteins and only a subset of these proteins has ‘dr...
Autores principales: | , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9412371/ https://www.ncbi.nlm.nih.gov/pubmed/36005826 http://dx.doi.org/10.3390/ncrna8040058 |
_version_ | 1784775477653667840 |
---|---|
author | Mirón-Barroso, Sofía Correia, Joana S. Frampton, Adam E. Lythgoe, Mark P. Clark, James Tookman, Laura Ottaviani, Silvia Castellano, Leandro Porter, Alexandra E. Georgiou, Theoni K. Krell, Jonathan |
author_facet | Mirón-Barroso, Sofía Correia, Joana S. Frampton, Adam E. Lythgoe, Mark P. Clark, James Tookman, Laura Ottaviani, Silvia Castellano, Leandro Porter, Alexandra E. Georgiou, Theoni K. Krell, Jonathan |
author_sort | Mirón-Barroso, Sofía |
collection | PubMed |
description | As research uncovers the underpinnings of cancer biology, new targeted therapies have been developed. Many of these therapies are small molecules, such as kinase inhibitors, that target specific proteins; however, only 1% of the genome encodes for proteins and only a subset of these proteins has ‘druggable’ active binding sites. In recent decades, RNA therapeutics have gained popularity due to their ability to affect targets that small molecules cannot. Additionally, they can be manufactured more rapidly and cost-effectively than small molecules or recombinant proteins. RNA therapeutics can be synthesised chemically and altered quickly, which can enable a more personalised approach to cancer treatment. Even though a wide range of RNA therapeutics are being developed for various indications in the oncology setting, none has reached the clinic to date. One of the main reasons for this is attributed to the lack of safe and effective delivery systems for this type of therapeutic. This review focuses on current strategies to overcome these challenges and enable the clinical utility of these novel therapeutic agents in the cancer clinic. |
format | Online Article Text |
id | pubmed-9412371 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-94123712022-08-27 Polymeric Carriers for Delivery of RNA Cancer Therapeutics Mirón-Barroso, Sofía Correia, Joana S. Frampton, Adam E. Lythgoe, Mark P. Clark, James Tookman, Laura Ottaviani, Silvia Castellano, Leandro Porter, Alexandra E. Georgiou, Theoni K. Krell, Jonathan Noncoding RNA Review As research uncovers the underpinnings of cancer biology, new targeted therapies have been developed. Many of these therapies are small molecules, such as kinase inhibitors, that target specific proteins; however, only 1% of the genome encodes for proteins and only a subset of these proteins has ‘druggable’ active binding sites. In recent decades, RNA therapeutics have gained popularity due to their ability to affect targets that small molecules cannot. Additionally, they can be manufactured more rapidly and cost-effectively than small molecules or recombinant proteins. RNA therapeutics can be synthesised chemically and altered quickly, which can enable a more personalised approach to cancer treatment. Even though a wide range of RNA therapeutics are being developed for various indications in the oncology setting, none has reached the clinic to date. One of the main reasons for this is attributed to the lack of safe and effective delivery systems for this type of therapeutic. This review focuses on current strategies to overcome these challenges and enable the clinical utility of these novel therapeutic agents in the cancer clinic. MDPI 2022-08-02 /pmc/articles/PMC9412371/ /pubmed/36005826 http://dx.doi.org/10.3390/ncrna8040058 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Review Mirón-Barroso, Sofía Correia, Joana S. Frampton, Adam E. Lythgoe, Mark P. Clark, James Tookman, Laura Ottaviani, Silvia Castellano, Leandro Porter, Alexandra E. Georgiou, Theoni K. Krell, Jonathan Polymeric Carriers for Delivery of RNA Cancer Therapeutics |
title | Polymeric Carriers for Delivery of RNA Cancer Therapeutics |
title_full | Polymeric Carriers for Delivery of RNA Cancer Therapeutics |
title_fullStr | Polymeric Carriers for Delivery of RNA Cancer Therapeutics |
title_full_unstemmed | Polymeric Carriers for Delivery of RNA Cancer Therapeutics |
title_short | Polymeric Carriers for Delivery of RNA Cancer Therapeutics |
title_sort | polymeric carriers for delivery of rna cancer therapeutics |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9412371/ https://www.ncbi.nlm.nih.gov/pubmed/36005826 http://dx.doi.org/10.3390/ncrna8040058 |
work_keys_str_mv | AT mironbarrososofia polymericcarriersfordeliveryofrnacancertherapeutics AT correiajoanas polymericcarriersfordeliveryofrnacancertherapeutics AT framptonadame polymericcarriersfordeliveryofrnacancertherapeutics AT lythgoemarkp polymericcarriersfordeliveryofrnacancertherapeutics AT clarkjames polymericcarriersfordeliveryofrnacancertherapeutics AT tookmanlaura polymericcarriersfordeliveryofrnacancertherapeutics AT ottavianisilvia polymericcarriersfordeliveryofrnacancertherapeutics AT castellanoleandro polymericcarriersfordeliveryofrnacancertherapeutics AT porteralexandrae polymericcarriersfordeliveryofrnacancertherapeutics AT georgioutheonik polymericcarriersfordeliveryofrnacancertherapeutics AT krelljonathan polymericcarriersfordeliveryofrnacancertherapeutics |